Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10(9)/L to <100 × 10(9)/L) at baseline: the final analysis of EXPAND

BACKGROUND: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF patients with low platelet counts (<100 × 10(9)/L). OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Guglielmelli, Paola, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Duan, Minghui, Meng, Haitao, Pan, Ling, He, Guangsheng, Verstovsek, Srdan, Boyer, Françoise, Barraco, Fiorenza, Niederwieser, Dietger, Pungolino, Ester, Liberati, Anna Marina, Harrison, Claire, Roussou, Pantelia, Wroclawska, Monika, Karumanchi, Divyadeep, Sinclair, Karen, te Boekhorst, Peter A.W., Gisslinger, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465569/
https://www.ncbi.nlm.nih.gov/pubmed/36105914
http://dx.doi.org/10.1177/20406207221118429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465569/
https://www.ncbi.nlm.nih.gov/pubmed/36105914
http://dx.doi.org/10.1177/20406207221118429

Ejemplares similares